论文部分内容阅读
目的:通过探讨定心胶囊对房颤大鼠血清D-二聚体含量的影响,揭示益气养阴活血中药预防和治疗房颤的作用机制。方法:选用体重在200～250 g的健康雄性Wistar大鼠,建立慢性房颤的动物模型。将造模成功的30只大鼠随机分为3组:模型组、定心胶囊治疗组(16.2 g·kg-1.d-1)和维拉帕米对照组(4.5 mg·kg-1.d-1),另设一组正常对照组。用药4周后,观察各组房颤大鼠血清D-二聚体的变化。结果:大鼠房颤模型组与正常对照组比较,血清D-二聚体的含量明显增加(P<0.05)。定心胶囊治疗组和维拉帕米对照组与模型组比较,可以明显地降低血清中D-二聚体的含量(P<0.05)。定心胶囊治疗组与维拉帕米对照组对房颤大鼠血清中D-二聚体的改善程度相比前者优于后者(P<0.05),有统计学意义。结论:定心胶囊能够明显降低房颤大鼠血清D-二聚体的水平,是防治房颤的有效药物。
Objective: To explore the effect of Dingxin Capsule on serum D-dimer in atrial fibrillation rats and to reveal the mechanism of Yiqi Yangyin Huoxue Chinese medicine in preventing and treating atrial fibrillation. Methods: Animal models of chronic atrial fibrillation were established in healthy male Wistar rats weighing 200-250 g. The 30 successful rats were randomly divided into 3 groups: model group, Dingxin capsule treatment group (16.2 g · kg-1.d-1) and verapamil control group (4.5 mg · kg-1. d-1), another set of normal control group. Four weeks after treatment, changes of serum D-dimer in atrial fibrillation rats were observed. Results: Compared with the normal control group, the content of D-dimer in the atrial fibrillation model group was significantly increased (P <0.05). Dingxin Capsule treatment group and verapamil control group compared with the model group, can significantly reduce the serum D-dimer levels (P <0.05). Dingxin Capsule treatment group and verapamil control group of atrial fibrillation serum D-dimer in the improvement of the former is better than the latter (P <0.05), with statistical significance. Conclusion: Dingxin Capsule can significantly reduce the level of serum D-dimer in atrial fibrillation rats, which is an effective drug in the prevention and treatment of atrial fibrillation.